The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1515
February 27, 2017
View Complete Issue         Table of Contents 2019 
Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
February 27, 2017 (Issue: 1515)
The FDA has approved extended-release (ER) calcifediol (25-hydroxyvitamin D3; Rayaldee – Opko), a prohormone of calcitriol, the active form of vitamin D3. It is indicated for treatment of secondary hyperparathyroidism (SHPT) in adults with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
Article code: 1515d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.